The four-year, $2.5-million grant, which includes collaboration with other researchers at Georgetown, as well as from Harvard and Columbia Universities, will address the question (#5 on the NCI's list of 24), “Given the evidence that some drugs commonly and chronically used for other indications, such as an anti-inflammatory drug, can protect against cancer incidence and mortality, can we determine the mechanism by which any of these drugs work?”
The National Cancer Institute has renewed its funding of the Yale Specialized Programs of Research Excellence in Skin Cancer grant over the next five years, for a total of $11.5 million. The grant supports multidisciplinary research in biomarkers and therapy targets based on Next-Gen DNA sequencing, genomics, and proteomic analyses. Ruth Halaban, PhD, Senior Research Scientist in the Department of Dermatology at Yale Cancer Center, is the project's principal investigator.
The Institute of Medicine and the Food and Drug Administration's Center for Tobacco Products have named the first FDA Tobacco Regulatory Science Fellows. The fellows will spend a year in Rockville, Md., where they will actively participate in the development of science-based public health strategies and lead specific projects related to tobacco product regulation. Each fellow will be assigned to one of three offices within CTP for the full year: the Office of Health Communication and Education, Office of Policy, and Office of Science. The 2012–2013 fellows are:
* Atanaska Dineva, communications associate, Institute for Global Tobacco Control, Johns Hopkins Bloomberg School of Public Health
* Candice Jongsma, PhD, research scientist, Conoco-Phillips, Bartlesville, Okla.
* Elizabeth Laposata, JD, research analyst, Center for Tobacco Control Research and Education, University of California, San Francisco.
The Ohio State University Com-prehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has announced the development of an international pancreatic cancer research effort to develop a collaboration with scientific investigators in Taiwan and Germany.
“We will bring multinational talent and will have access to a robust tumor bank for pancreatic cancer, which will help to speed drug discovery and cure for this dreadful disease,” Tanios Bekaii-Saab, MD, Section Chief of the Section of Gastrointestinal Oncology, said in a statement.
Bekaii-Saab will partner with Pin-Win Lin, MD, Professor in the Graduate Institute of Clinical Medicine and School of Medicine in the Department of Surgery and Superintendent of National Cheng Kung University Hospital in Taiwan; Yan-Shen Shan, PhD, and Po-Hsien Huang, PhD, both Assistant Professors at Cheng Kung; Ching-Shih Chen, PhD, Professor of Internal Medicine at Cheng Kung; Mark Bloomston, MD, Director of OSU's Surgical Oncology Fellowship Program; and Christoph Plass, PhD, Head of the Division of Epigenomics and Cancer Risk Factors at the German Cancer Research Center.
The Wistar Institute will receive a $1 million grant from Pennsylvania's Commonwealth Universal Research Enhancement Pro-gram to support research to develop a blood test for lung cancer. Louise C. Showe, PhD, Professor in the Molecular & Cellular Oncology Program and Director of the Genomics and Bioinformatics facilities, who will lead the research, said in a statement, “Our recent published studies show that with a simple blood draw, we can detect lung cancer, show the effectiveness of cancer surgery, by sampling the same patient's blood for analysis after surgery, and even determine if the cancer may return. We are working to further validate and expand our findings by studying more patient samples so that we have enough evidence to take this concept into clinical trials.”
The Oncology Nursing Certification Corporation will be offering a new certification program in blood and marrow transplantation nursing, covering autologous and allogeneic transplantation in adult and pediatric patients. The Blood and Marrow Transplantation Certified Nurse Examination will be offered for the first time in February 2014.
“As the field of blood and marrow transplantation has evolved, nurses in the specialty have developed a unique body of knowledge. BMTCN certification will validate that knowledge,” the Executive Director, Cyndi Miller Murphy, MSN, RN, CAE, said in a statement.
The American Association for Cancer Research is accepting nominations for its annual series of awards and lectureships. Recipients will be honored at the 2013 AACR Annual Meeting, to be held April 6–10 in Washington, DC. More information is available at www.AACR.org/ScientificAwards
Correction: In the August 25th issue, the organizations that awarded the 2012 Susan Matsuko Shinagawa LIVESTRONG Cancer Control Leadership Award to COL (Ret.) James E. Williams, Jr., U.S. Army, MS, SPHR, and Olga G. Sánchez, Community Health Program Representative at San Diego State University/University of California San Diego Cancer Center Comprehensive Partnership, were incorrectly listed. The awards were presented by the Intercultural Cancer Council and the Lance Armstrong Foundation at the ICC's 25th Anniversary Biennial Symposium on Minorities, the Medically Underserved & Health Equity.
Leukemia & Lymphoma Society Awards $12 Million in Research Grants to Address Four ‘Critical Areas of Unmet Medical Need’
The Leukemia & Lymphoma Society has awarded 20 grants, totaling $12 million, under its Translational Research Program, an initiative designed to accelerate the movement of promising discoveries from the lab to the clinic. Each grant awards $600,000 over three years.
The grants were awarded to the following individuals to address these four areas of high, unmet medical need in blood cancers:
The leukemic stem cell in AML and MDS and the identification of potential targeted therapies:
* Alan D'Andrea, MD, Dana-Farber Cancer Institute
* James Griffin, MD, Dana-Farber Cancer Institute
* H. Leighton Grimes, PhD, Children's Hospital Medical Center of Cincinnati
* Guzman, PhD, Joan & Sanford I. Weill Medical College of Cornell University
* Duane Hassane, PhD, Joan & Sanford I. Weill Medical College of Cornell University
* Anthony Letai, MD, PhD, Dana-Farber Cancer Institute
* Ross Levine, MD, Memorial Sloan-Kettering Cancer Center
* A. Thomas Look, MD, Dana-Farber Cancer Institute
* Li Zhang, MSc, MD, PhD, University Health Network
Novel therapeutic strategies for non-cutaneous T-cell lympho-proliferative disorders:
* Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic Foundation
* Owen O'Connor, MD, PhD, Columbia University
Development of therapeutic strategies for high-risk myeloma:
* Jennifer Carew, PhD, University of Texas Health Science Center at San Antonio
* Irene Ghobrial, MD, Dana-Farber Cancer Institute
* Christoph Heuck, MD, University of Arkansas for Medical Sciences
* Alexander Stewart, MD, Mayo Clinic
Mechanisms underlying long-term and late effects related to cancer treatment and the development of measures to reduce or prevent these toxicities:
* Smita Bhatia, MD, MPH, City of Hope
* Eric Chow, MPH, Fred Hutchinson Cancer Research Center
* Ruben Niesvizky, MD, Joan & Sanford I. Weill Medical College of Cornell University
* Pavan Reddy, MD, University of Michigan
* Daniela Salvemini, PhD, Saint Louis University.
Share Your Good News!
Send information and photos for this column to OT@LWWNY.com© 2012 Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...